Drugs / Tree MATA MPL
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00107705 | Apr → May 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00387478 | Oct 2006 → Jul 2007 | hypersensitivity reaction disease | Allergy Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00118612 | Jul → Sep 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00118625 | Jul → Sep 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00113750 | Jul → Dec 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tree MATAMPL | “Tree MATAMPL (tyrosine adsorbed tree pollen allergoid with monophosphoryl lipid A (MPL®)) has been developed to provide pre-seasonal specific immunotherapy for patients with...” NCT00118612 ↗5“Tree MATA MPL has been developed to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to tree (birch, alder, and hazel) pollen.” NCT00113750 ↗ |
| Known as | Tree MATA | “Tree MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to tree (birch,...” NCT00113750 ↗ |
| Modality | Other / unclassified | “The tree pollen extract is modified with glutaraldehyde to produce the active ingredient, an allergoid.” NCT00107705 ↗ |
| Route | Subcutaneous | “following 2 subcutaneous injections of different doses of study medication (Tree MATA) or placebo administered 3 weeks apart” NCT00113750 ↗ |